December.05.2018
Orrick has advised Silicon Valley-based PhyNexus on its acquisition by Biotage AB (Nasdaq Stockholm: BIOT.ST), a Swedish public company which is a global supplier of instruments and consumables for analytical, organic and peptide chemistry. The total purchase price is $21.5 million financed by Biotage through a combination of newly issued shares in Biotage (to be listed on the Stockholm NASDAQ) and existing cash on hand.
This cross border transaction is expected to be completed in January 2019 and is subject to customary closing conditions.
The Orrick team was led by M&A and private equity partner Richard V. Smith and included Scott Iyama (Technology Companies), Stephen Chao (M&A and private equity), Nancy Chen (compensation and benefits) and Steve Malvey (tax).